Skip to content

Virtual Visitation in Intensive Care Unit Study

Efficacy of Virtual Visitation in Intensive Care Unit During COVID-19 Pandemic: Randomized Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04962204
Acronym
ISEEU
Enrollment
100
Registered
2021-07-14
Start date
2021-07-06
Completion date
2022-06-30
Last updated
2021-10-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critically Ill Patients

Brief summary

The purpose of this study is to identify the efficacy of virtual visitation in Intensive Care Unit on patients and their caregivers during COVID-19 Pandemic.

Detailed description

After being informed about the study, all patients who meet the eligibility requirements will be randomized in a 1:1 ratio to intervention group (Virtual visitation once a day) or Control group (Phone interviews once a day).

Interventions

BEHAVIORALVirtual meeting between patients/physicians and caregiver

Virtual visits between patients-caregivers and virtual interviews between physicians-caregivers for 15minutes once a day

Sponsors

Seoul National University Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

Interventional group Control group

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who are expected to stay in the intensive care unit for more than 48 hours * Patients with a RASS score of -2 or higher

Exclusion criteria

* Patients who discharge or die within 48 hours of admission to ICU

Design outcomes

Primary

MeasureTime frameDescription
FS-ICU score from caregivers at discharge or 7 days after initiation of study enrolled7 daysThe FS-ICU survey score reflected the satisfaction degree of caregivers. The overall satisfaction score is derived from questions 1 through 24.

Countries

South Korea

Contacts

Primary ContactSeung-Young Oh
faun1226@gmail.com+82-2-2072-3538

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026